Opill AdCom Delay Not Unusual – Will Evaluation Of US OTC Switch Proposal Continue In The Norm?
Executive Summary
Whether FDA handling of HRA Pharma’s OTC switch NDA for 0.075-mg norgestrel continues along normal arc is question which prompts concerns. “I hope that they don't make the same mistakes that were made back on the Plan B,” says Susan Wood, an associate professor at George Washington University School of Public Health and a former FDA office director.
You may also be interested in...
Year After Acquisition, Perrigo Waits For US Decision On HRA’s OTC Oral Contraceptive Switch
Wait will be as long as another three months to learn whether HRA will have approval to market OTC a product Perrigo estimates will have $100m in annual sales.
Perrigo Results Mirror Previous Year After 2022 Made Momentous With OTC Contraceptive Play
Day ahead of investor day conference, Perrigo releases 2022 fourth-quarter and full-year results. Its full-yearr net loss for each of past two years was the same.
US Q4 Consumer Health Earnings Preview: Will Demand Or Shortage Have More Impact?
Demand for OTC pain relievers and cough/cold products jumped prior to October-December and remained high during quarter due to consumer concern not only about flu but also RSV and additional COVID-19 mutation. US and Canadian firms marketing OTC drugs and supplements also will be offering additional signals on planned spinoffs of consumer health businesses.